✦ LIBER ✦

Impact of second-line and later cetuximab-containing therapy andKRASgenotypes in patients with metastatic colorectal cancer: a multicenter study in Japan

✍ Scribed by Saeki, Hiroshi; Emi, Yasunori; Kumashiro, Ryuichi; Otsu, Hajime; Kawano, Hiroyuki; Ando, Koji; Ida, Satoshi; Kimura, Yasue; Tokunaga, Eriko; Oki, Eiji; Morita, Masaru; Shimokawa, Mototsugu; Maehara, Yoshihiko

Book ID: 125349594
Publisher: Springer
Year: 2013
Tongue: English
Weight: 347 KB
Volume: 44
Category: Article
ISSN: 1436-2813
DOI: 10.1007/s00595-013-0716-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab plus irinotecan, 5-fluoroura

Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study

✍ Deng, Ting; Zhang, Le; Liu, Xiao-jian; Xu, Jian-ming; Bai, Yu-xian; Wang, Yan; H 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 199 KB

6122 POSTER Impact of Cetuximab-based Th

6122 POSTER Impact of Cetuximab-based Therapy and KRas Genotypes in Japanese Patients With Chemotherapy-refractory Metastatic Colorectal Cancer

✍ Kohnoe, S.; Saeki, H.; Emi, Y.; Ando, K.; Ohga, T.; Oki, E.; Ikeda, T.; Tsujitan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Dose escalating study of cetuximab and 5

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

✍ Gunnar Folprecht,Susanne Hamann,Katharina Schütte,Tanja Trarbach… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 460 KB

A Phase II Trial of FOLFOX6 and Cetuxima

A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer

✍ Ralph V. Boccia; Thomas M. Cosgriff; David L. Headley; Suprith Badarinath; Shake 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 410 KB

3046 POSTER A randomized, open-label pha

3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer

✍ T.E. Ciuleanu; W. Scheithauer; G. Kurteva; J. Ocvirk; I. Koza; D. Papamichael; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Validation study of a prognostic classif

Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy

✍ Shitara, Kohei; Yuki, Satoshi; Yamazaki, Kentaro; Naito, Yoichi; Fukushima, Hira 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 251 KB